argenx SE (NASDAQ:ARGX – Get Rating) was the recipient of unusually large options trading on Tuesday. Traders purchased 4,259 call options on the stock. This represents an increase of approximately 919% compared to the average volume of 418 call options.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARGX. JPMorgan Chase & Co. grew its holdings in argenx by 143.0% in the 1st quarter. JPMorgan Chase & Co. now owns 1,577 shares of the company’s stock valued at $497,000 after buying an additional 928 shares in the last quarter. Raymond James & Associates lifted its position in shares of argenx by 19.4% during the 1st quarter. Raymond James & Associates now owns 4,534 shares of the company’s stock valued at $1,430,000 after acquiring an additional 738 shares during the period. Raymond James Financial Services Advisors Inc. lifted its position in shares of argenx by 46.0% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 3,544 shares of the company’s stock valued at $1,117,000 after acquiring an additional 1,116 shares during the period. Bank of New York Mellon Corp lifted its position in shares of argenx by 4.4% during the 1st quarter. Bank of New York Mellon Corp now owns 6,447 shares of the company’s stock valued at $2,033,000 after acquiring an additional 271 shares during the period. Finally, US Bancorp DE lifted its position in shares of argenx by 43.0% during the 1st quarter. US Bancorp DE now owns 1,798 shares of the company’s stock valued at $566,000 after acquiring an additional 541 shares during the period. 57.29% of the stock is owned by institutional investors and hedge funds.
argenx Stock Down 0.8 %
ARGX stock opened at $374.79 on Wednesday. argenx has a fifty-two week low of $267.35 and a fifty-two week high of $407.93. The company has a 50-day simple moving average of $365.11 and a 200 day simple moving average of $371.92. The company has a market capitalization of $20.79 billion, a P/E ratio of -28.54 and a beta of 0.74.
Analyst Upgrades and Downgrades
ARGX has been the subject of several research analyst reports. SVB Leerink raised their price objective on shares of argenx from $430.00 to $435.00 and gave the stock an “outperform” rating in a report on Friday, March 3rd. Stifel Nicolaus lifted their price target on shares of argenx from $471.00 to $478.00 and gave the company a “buy” rating in a report on Thursday, December 22nd. JMP Securities boosted their target price on shares of argenx from $443.00 to $448.00 and gave the stock a “market outperform” rating in a report on Friday, March 3rd. SVB Securities boosted their target price on shares of argenx from $430.00 to $435.00 in a report on Friday, March 3rd. Finally, Robert W. Baird upgraded shares of argenx from a “neutral” rating to an “outperform” rating and set a $460.00 target price on the stock in a report on Tuesday, March 14th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $454.64.
About argenx
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
Featured Articles
- Get a free copy of the StockNews.com research report on argenx (ARGX)
- Weight Watchers Reshapes Itself with a Game-Changer Acquisition
- Nano Dimension Prints Growth: Enters Hypergrowth Phase
- Two Tiny Mining Stocks Worth Considering for the Next Gold Rush
- CF Is Set To Harvest The Bull Run In Agricultural Stocks
- Oracle Dips But The Trend Is Strong
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.
